期刊文献+

远端上游元件结合蛋白1在胃癌中的表达及其对胃癌细胞增殖和侵袭能力的影响 被引量:3

Expression of Far Upstream Element Binding Protein 1 in Gastric Cancer and Its Effect on Proliferation and Invasion of Gastric Cancer Cells
下载PDF
导出
摘要 目的研究远端上游元件结合蛋白1(FUBP1)在胃癌中的表达,探讨其对胃癌细胞增殖侵袭能力的影响。方法采用实时PCR检测FUBP1基因在胃癌组织中的表达。采用单因素方差分析分析FUBP1基因表达与胃癌临床病理因素的相关性。构建FUBP1基因表达沉默载体p S-FUBP1并转染SGC7901细胞,实时PCR检测转染效果。采用CCK8法及Transwell法检测FUBP1基因表达沉默对于SGC7901细胞的增殖和侵袭能力的影响。结果 FUBP1基因在胃癌组织中表达显著上调,且随着分化水平的降低、浸润深度和转移淋巴结数量的增加,胃原发癌中FUBP1基因表达明显增高。p S-FUBP1载体能够显著沉默FUBP1基因的表达。FUBP1表达沉默的SGC7901细胞的增殖及侵袭能力下调明显。结论 FUBP1基因在胃癌中高表达,与胃癌的发生进展相关,沉默其表达能够抑制胃癌细胞的增殖和侵袭能力。 Objective To investigate the expression of far upstream element binding protein 1 (FUBP1) gene in gastric cancer, and analyze its effect on proliferation and invasion of gastricc cancer cells. Methods The expression of FUBP1 in gastric cancer tissues was detected by real-time PCR. The relationship between FUBP1 expression and clinic pathological factors of gastricc cancer was analyzed by one-way ANOVA. The silence vector for FUBPI was constructed and transfected into gastricc cancer SGC7901 cells, and the transfected effects were then detected by real-time PCR. The influence of FUBP1 silence on cell proliferation and invasion in SGC7901 cells were detected by CCK8 method and Transwell assay. Resuits FUBP1 expression was increased markedly in gastricc cancer tissues. Following the depressing of differentiation and the increase of invasion depth and metastatic lymph nodes, the FUBP1 expression was up-regulated in primary gastric carcinoma significantly. The pS-FUBP1 vector could silence the FUBPI expression in SGC7901 cells. FUBP1 silence inhibited SGC7901 cell proliferation anld invasion. Conclusion FUBP1 was high-expressed in gastricc cancer, and related with genesis and progress of gastric cancer, silence of FUBP1 expression can inhibit the cell proliferation and invasion in gastric cancer cells.
出处 《中国医科大学学报》 CAS CSCD 北大核心 2017年第7期587-590,共4页 Journal of China Medical University
基金 国家自然科学基金(81272716)
关键词 胃癌 远端上游元件结合蛋白1 增殖 侵袭 gastric cancer FUBP1 proliferation invasion
  • 相关文献

参考文献1

二级参考文献20

  • 1Yoon-Koo Kang,Kei Muro,Min-Hee Ryu,Hirofumi Yasui,Tomohiro Nishina,Baek-Yeol Ryoo,Yukimasa Kamiya,Shiro Akinaga,Narikazu Boku.A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer[J].Investigational New Drugs.2014(2)
  • 2Hansjochen Wilke,Kei Muro,Eric Van Cutsem,Sang-Cheul Oh,Gy?rgy Bodoky,Yasuhiro Shimada,Shuichi Hironaka,Naotoshi Sugimoto,Oleg Lipatov,Tae-You Kim,David Cunningham,Philippe Rougier,Yoshito Komatsu,Jaffer Ajani,Michael Emig,Roberto Carlesi,David Ferry,Kumari Chandrawansa,Jonathan D Schwartz,Atsushi Ohtsu.Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial[J]. Lancet Oncology . 2014 (11)
  • 3Subhajit Roy,Bawneet K. Narang,Shiva K. Rastogi,Ravindra K. Rawal.A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib[J]. Anti-Cancer Agents in Medicinal Chemistry . 2015 (1)
  • 4Hua Liu,Changlin Qian,Zhiyong Shen.Anti-tumor activity of oridonin on SNU-5 subcutaneous xenograft model via regulation of c-Met pathway[J]. Tumor Biology . 2014 (9)
  • 5Paul R. Gavine,Yongxin Ren,Lu Han,Jing Lv,Shiming Fan,Wei Zhang,Wen Xu,Yuan Jie Liu,Tianwei Zhang,Haihua Fu,Yongjuan Yu,Huiying Wang,Shirlian Xu,Feng Zhou,Xinying Su,XiaoLu Yin,Liang Xie,Linfang Wang,Weiguo Qing,Longxian Jiao,Weiguo Su,Q. May Wang.Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models[J]. Molecular Oncology . 2014
  • 6Charles S Fuchs,Jiri Tomasek,Cho Jae Yong,Filip Dumitru,Rodolfo Passalacqua,Chanchal Goswami,Howard Safran,Lucas Vieira dos Santos,Giuseppe Aprile,David R Ferry,Bohuslav Melichar,Mustapha Tehfe,Eldar Topuzov,John Raymond Zalcberg,Ian Chau,William Campbell,Choondal Sivanandan,Joanna Pikiel,Minori Koshiji,Yanzhi Hsu,Astra M Liepa,Ling Gao,Jonathan D Schwartz,Josep Tabernero.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial[J]. The Lancet . 2014 (9911)
  • 7Guy Betts,Helen Valentine,Sue Pritchard,Richard Swindell,Victoria Williams,Shethah Morgan,Ewen A. Griffiths,Ian Welch,Catharine West,Christopher Womack.FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation[J]. Virchows Archiv . 2014 (2)
  • 8Sang-Won Hong,Kyung-Hee Jung,Byung Hee Park,Hong-Mei Zheng,Hee-Seung Lee,Myung-Joo Choi,Jeong In Yun,Nam Sook Kang,Jongkook Lee,Soon-Sun Hong.KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer[J]. Cancer Letters . 2013 (1)
  • 9Magali Humbert,Michaela Medová,Daniel M. Aebersold,Andree Blaukat,Friedhelm Bladt,Martin F. Fey,Yitzhak Zimmer,Mario P. Tschan.Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells[J]. Biochemical and Biophysical Research Communications . 2013 (2)
  • 10Julia Kneissl,Simone Keller,Thomas Lorber,Stefan Heindl,Gisela Keller,Ingo Drexler,Alexander Hapfelmeier,Heinz H?fler,Birgit Luber.Association of amphiregulin with the cetuximab sensitivity of gastriccancer cell lines[J]. International Journal of Oncology . 2012 (2)

共引文献4

同被引文献10

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部